Ionis Pharma's genetic disease drug succeeds in late-stage study

Ionis Pharmaceuticals' experimental drug, donidalorsen, administered through subcutaneous injection, showed a significant reduction in the rate of painful attacks for patients with hereditary angioedema. The patients received an 80 milligram dose of the drug every four or eight weeks.

from Science News - Times of India https://ift.tt/eKoNTbi